Common Side Effects of Cosentyx in Elderly Patients
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, carries risks that may hit older adults harder due to age-related declines in immune function and organ health. Upper respiratory infections occur in about 15-20% of patients overall, but elderly users (65+) report higher rates of serious infections like pneumonia or cellulitis, per clinical trial data.[1][2]
Why Infections Pose Bigger Risks for Seniors
Elderly patients face elevated odds of severe infections—up to 2-3 times higher than younger groups—because Cosentyx suppresses immune responses. Trials showed infection rates rising with age, with 65+ patients experiencing 25-30% incidence vs. 10-15% in under-65s. Watch for fever, cough, or skin redness, as delays can lead to hospitalization.[1][3]
Increased Chance of Inflammatory Bowel Disease
New-onset or worsening Crohn's disease or ulcerative colitis affects 1-2% of users, but elderly patients with prior gut issues see higher flares. FDA labeling flags this as a black-box concern, with seniors over 65 at greater risk due to thinner intestinal linings and comorbidities.[2][4]
What About Cancer and Heart Risks?
Long-term data links IL-17 blockers to slight upticks in malignancies (e.g., non-melanoma skin cancer) in older adults, though causality isn't proven—rates hover around 1-2% after 2+ years. Cardiovascular events like heart failure exacerbations also rise in those with pre-existing conditions, common in seniors.[1][5]
How Does Age Affect Dosing and Monitoring?
No dose adjustments for age alone, but doctors recommend closer monitoring: baseline TB tests, regular bloodwork, and vaccines before starting. Elderly patients on steroids or with diabetes need extra caution, as these amplify infection risks.[2][3]
Comparisons with Other Biologics for Seniors
Vs. TNF inhibitors like Humira, Cosentyx shows similar infection rates but fewer injection-site reactions (5-10% vs. 15%). Enbrel may edge it on heart safety in 65+ patients, per head-to-head studies.[5][6]
Sources
[1]: Cosentyx Prescribing Information (Novartis)
[2]: FDA Label for Secukinumab
[3]: ClinicalTrials.gov: SCULPTURE Trial (NCT01365455)
[4]: Drugs.com: Cosentyx Side Effects
[5]: JAMA Dermatology: Safety in Elderly Psoriasis Patients (2020)
[6]: Annals of Rheumatic Diseases: Biologic Comparisons in Seniors